Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

Blood cells

The team has previously shown that development of myofibroblasts, the cells responsible for deposition of the excessive matrix and contraction, is dependent on production of tumour necrosis factor (TNF) by local immune cells. The research, published in PNAS showed that endothelial cells lining the blood vessels modulate the activity of immune regulatory fibroblasts, which secrete mediators that attract the immune cells. They also identified that a potential myofibroblast precursor cell that is contained within a compartment of cells called pericytes that wrap around the blood vessel wall.

First author on the paper, Dr Thomas Layton, who started the work the work as a Kennedy DPhil student at the Kennedy Institute said: "This study illustrates the potential of using state of the art molecular biology techniques to relatively under studied diseases."

Fibrotic diseases, such as idiopathic pulmonary fibrosis, liver cirrhosis and chronic kidney disease, all result from excessive scarring of tissues leading to progressively worsening organ function. Although these diseases have high morbidity and mortality in the Western world, research has been limited by difficulty accessing tissues at the earliest stages of disease. In contrast, in Dupuytren's disease, affected tissues from the palm of the hand are relatively easy to obtain, and can provide clues into fibrotic pathways and possible approaches to slow down or halt disease.

"Animal models fail to recapitulate all aspects of human fibrosis," said Professor Nanchahal. "The pathways we identified using tissue from patients with Dupuytren's disease also appear to pertain to other human fibrotic diseases, such as idiopathic pulmonary fibrosis."

The work was supported by an Oxford-BMS/Celgene fellowship, Royal College of Surgeons of England and British Society for Surgery of the Hand.

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.